Automate Your Wheel Strategy on INCY
With Tiblio's Option Bot, you can configure your own wheel strategy including INCY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INCY
- Rev/Share 23.6519
- Book/Share 30.0297
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.149
- MktCap 14624219640.0
- FreeCF/Share 1.4898
- PFCF 50.6361
- PE 16.6703
- Debt/Assets 0.0
- DivYield 0
- ROE 0.3386
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INCY | Barclays | -- | Overweight | -- | $90 | Aug. 1, 2025 |
| Upgrade | INCY | Stifel | Hold | Buy | -- | $107 | June 16, 2025 |
| Downgrade | INCY | Guggenheim | Buy | Neutral | -- | -- | March 18, 2025 |
| Downgrade | INCY | William Blair | Outperform | Market Perform | -- | -- | March 18, 2025 |
| Initiation | INCY | UBS | -- | Neutral | -- | $77 | Dec. 17, 2024 |
| Initiation | INCY | Wolfe Research | -- | Outperform | -- | $84 | Oct. 1, 2024 |
| Downgrade | INCY | Truist | Buy | Hold | $83 | $74 | Sept. 18, 2024 |
News
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2025--Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting.
Read More
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del. & BURLINGAME, Calif.--(BUSINESS WIRE)--Incyte and Genesis Therapeutics announce strategic AI-focused research collaboration.
Read More
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
Read More
Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Tazeen Ahmad - Bank of America David Lebowitz - Citibank Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Marc Frahm - TD Cowen Kelly Shi - Jefferies Brian Abrams - …
Read More
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.
Read More
About Incyte Corporation (INCY)
- IPO Date 1993-11-04
- Website https://www.incyte.com
- Industry Biotechnology
- CEO Herve Hoppenot
- Employees 2617